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Genomewide association studies (GWAS) have made a 
phenomenal contribution to our understanding of 
common heritable diseases over the past 4 years. 
Immuno genetics research in particular has been highly 
successful in identifying large numbers of genetic loci. 
Th ese fi ndings have greatly advanced our understanding 
of the basic causes of autoimmune and infl ammatory 
conditions, and have provided a solid foundation for 
hypothesis-driven research into disease mechanisms. As 
the boundaries of GWAS have been tested, however, 
limitations of the approach have become more apparent.
It is clear that a substantial fraction of the heritability of 
common diseases, even in diseases for which quite large 
GWAS have been performed, has not been mapped, 
raising questions as to where the missing heritability lies 
[1]. Th eories regard ing the location of the unmapped 
heritability include: residual unidentifi ed common 
variant associa tions (common disease–common variant 
model), rare variant associations not mapped because 
they are poorly captured by common tagSNPs (common 
disease–rare variant model), copy number variants 
(CNVs), epigenetic eff ects, gene–gene interactions and 
gene–environment interactions.
Further, the true associated variants are uncertain for 
most identifi ed loci – even though GWAS have far better 
resolution than the linkage studies preceding the GWAS 
era. Even high-density mapping with common SNPs has 
in most cases not been able to distinguish an association 
signal due to direct association with disease risk from an 
indirect association signal due to linkage disequilibrium 
eff ects.
Common CNVs are an unlikely source of much missing 
heritability. Of the 95 loci known by SNP studies at the 
end of 2009 to be associated with Crohn’s disease and 
type 1 and type 2 diabetes, only three harbored CNVs 
that may explain the association [2]. In an extensive study 
of the role of CNVs in eight common diseases, the 
Wellcome Trust Case Control Consortium identifi ed just 
three CNV associations, each of which had already been 
identifi ed by tagSNP studies [2]. Th e study concluded 
that ‘common CNVs which can be typed on existing 
platforms are unlikely to contribute greatly to the genetic 
basis of common diseases’. Whether epigenetic eff ects 
can contribute to heritability of common diseases is un-
clear, as the evidence for heritable transmission of epi-
genetic marks from generation to generation is limited in 
humans [3] – although defi nitive studies are awaited, and 
they may be tagged by SNP studies anyway [4]. Most 
heritability studies report narrow-sense heritability, which 
is heritability excluding gene–gene interaction; thus 
gene–gene interaction does not contribute to missing 
narrow-sense heritability. Gene–environment interaction 
studies in most diseases are in their infancy, and the 
contri bution of such interactions to heritability is 
unknown.
Recent modeling studies suggest that the missing 
heritability lies in a mixture of unmapped common and 
rare variants [5]. Rare variants may have larger functional 
eff ects than common variants, which can only become 
common in a population if they do not have a signifi cance 
adverse eff ect on survival/health, or if they are removed 
from populations by natural selection. Rare variants may 
also have higher genetic resolution, helping to pinpoint 
the key regions underlying genetic associations.
Current genotyping chips used for GWAS are not well 
suited to either picking up the remaining common 
variants or identifying rare variants. Th e sample size 
required to identify the remaining common variants in 
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most common diseases once the low-hanging fruit have 
been identifi ed is massive. For example, a recent meta-
analysis of GWAS data on the model phenotype height 
studied 183,727 individuals and identifi ed 180 loci; these 
contributed just 20% of the heritable component of 
height variation [6]. At a rough GWAS genotyping cost of 
US$250 per sample nowadays, this type of study is clearly 
unaff ordable for most diseases even if there were enough 
cases available. Most of the remaining common variants 
are thought to probably be contained amongst the most 
strongly associated SNPs, however, even if they have not 
yet achieved defi nite levels of association.
Th e current crop of GWAS chips does not identify rare 
variants very well either. Genotyping companies are now 
racing to increase rare variant coverage on genotyping 
chips, but even very high-density chips such as the 
5  million SNP chips in the Illumina pipeline will only 
sample a small fraction of the 3.3 billion bases in the 
human genome. In the dbSNP database there are 
currently ~12 million annotated SNPs, and a further 
32 million awaiting annotation. Ultimately, this coverage 
issue will be solved by whole genome sequencing studies, 
but these remain too expensive for widespread use. 
Further, the sample sizes required to map rare variants 
are much higher than for common variants, unless those 
rare variants have quite large individual eff ects. Adequately 
powered rare variant mapping studies using these new, 
denser, GWAS chips are therefore going to be very 
expensive.
At least part of the answer to these problems lies in the 
development of custom genotyping chips such as the 
Immunochip designed for immunogenetics studies, the 
Metabochip designed for studying metabolic diseases, 
and a cardiovascular disease chip [7]. Immunochip is an 
Illumina Infi nium genotyping chip, containing 196,524 
poly morph isms (718 small insertion deletions, 195,806 
SNPs) designed both to perform deep replication of 
major autoimmune and infl ammatory diseases, and fi ne-
mapping of established GWAS signifi cant loci. Initiated 
by the Wellcome Trust Case–Control Consortium, 
Immunochip was designed by a consortium of leading 
investigators covering all of the major autoimmune and 
seronegative diseases, many of interest to rheumato-
logical researchers, including rheumatoid arthritis, 
ankylosing spondylitis and systemic lupus erythematosus, 
as well as the related autoimmune conditions type 1 
diabetes, autoimmune thyroid disease, celiac disease and 
multiple sclerosis, and the seronegative diseases ulcera-
tive colitis, Crohn’s disease, and psoriasis. SNPs for deep 
replication were also included from the fi ndings of 
GWAS performed on non-immunological diseases that 
were studied as part of the Wellcome Trust Case–Control 
Consortium 2 [8]. For each disease, ~3,000 SNPs were 
selected from available GWAS data for deep replication, 
as well as to cover strong candidate genes. Th e chip will 
thus enable deep replication studies to identify which 
amongst the top-ranked SNPs in GWAS studies are truly 
disease associated. Further, because these diseases are 
genetically related, the chip will lead to pleiotropic genes 
being identifi ed, which are associated with more than 
one of the diseases for which the chip was designed.
At loci with established disease association, the chip 
contains all known SNPs in the dbSNP database, from 
the 1000 Genomes project (February 2010 release), and 
from any other sequencing initiatives that were available 
to the consortium. Th is enables cost-eff ective fi ne-
mapping of loci for both rare and common variants. Th is 
fi ne-mapping would only be possible otherwise if each 
individual disease produced custom genotyping chips to 
investigate their particular disease-associated loci, a 
much more expensive proposition due to the far smaller 
production runs this would entail.
Th e chip also contains a dense set of SNPs in the MHC, 
which will enable imputation of the major classical HLA 
loci. Although this approach has been previously valid-
ated in white Britons, and in African and non-African 
samples from the HapMap database [9], further confi r-
mation in additional cohorts is being performed by the 
Immunochip Consortium. A dense SNP set across the 
KIR/LILR complex is also included to allow imputation 
of KIR and LILR alleles. Ancestry informative markers 
are included to allow identifi cation and control of 
population stratifi cation eff ects.
Th e cost of the Immunochip is far lower than GWAS 
chips (~US$39/sample) because it has been produced in 
very large numbers (>150,000 ordered in the initial batch). 
Th is has enabled groups to fi nance genotyping of very 
large cohorts – for example, the International Genetics of 
Ankylosing Spondylitis Consortium will complete a case 
study of 12,000 participants by early next year, something 
unaff or dable should it be attempted using GWAS chips. 
Th e Immunochip Consortium are sharing control data 
that will be available for most ethnic groups; more than 
20,000 white European controls are expected to be 
available. Th e study sample size will thus be suffi  cient to 
map rare variants without blowing the bank.
Weaknesses of the Immunochip approach include the 
following. Th e chip is designed for use in white European 
populations and will therefore be less informative for 
other ethnic groups, although the chip will still be 
informative particularly where disease-associated 
variants and haplotypes are shared between white Euro-
peans and the specifi c ethnic group studied. Another 
weakness is that many rare variants have yet to be 
identifi ed and are thus not represented on the chip. 
Th ird, genotyping rare variants is a diffi  cult process – and 
although early indications are that the chip performs 
well, a proportion of particularly the rarer variants will 
Cortes and Brown Arthritis Research & Therapy 2011, 13:101 
http://arthritis-research.com/content/13/1/101
Page 2 of 3
probably not be accurately genotyped by the chip. Th e 
Immunochip also does not type rare CNVs, which are 
not well captured by tagSNP studies. A fi nal weakness is 
that the chip does not cover the whole genome, and 
depends on the power of the initial GWAS studies for its 
marker selection. Th e chip, particularly for diseases 
where fewer cases have had GWAS performed, will 
therefore miss residual associated loci.
Th e Immunochip will thus enable some very valuable 
and relatively inexpensive studies. For complex problems, 
however, there is rarely a single comprehensive solution, 
and genetics is no exception to this rule. Future progress 
in gene mapping will probably involve a range of diff erent 
methods, including GWAS, sequencing, and targeted, 
informed genotyping strategies such as the Immunochip.
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